<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867672</url>
  </required_header>
  <id_info>
    <org_study_id>00332/AMLSG14-09</org_study_id>
    <nct_id>NCT00867672</nct_id>
  </id_info>
  <brief_title>Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia</brief_title>
  <acronym>DECIDER</acronym>
  <official_title>Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients &gt; 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AML of the older patient constitutes a major unmet clinical need since the large majority
      will not be found eligible for induction chemotherapy. Reasons for this decision include host
      factors (comorbidities, reduced performance status, functional limitations due to age),
      leading to often poor tolerance of repeated chemotherapy courses and the unfavorable biology
      underlying this disease in older patients. Low dose Decitabine has shown very promising
      efficacy in high-risk MDS and is therefore a very promising approach also in older AML
      patients. Preliminary results from several centres have demonstrated excellent feasibility
      and good efficacy of this treatment. Therefore the investigators intend to investigate the
      effects of two drugs added onto low-dose Decitabine which have shown very promising
      synergistic effects in vitro and for which preliminary results indicate that the combination
      with low-dose Decitabine is very feasible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By employing a 2x2 factorial design, this phase II study will address the possible added
      efficacy of addition of one or even both of these agents to low-dose Decitabine. The primary
      endpoint of this study will be objective response rate (complete and partial remissions).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective best response rate (complete remission (CR) and partial remission (PR))</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall best response rate (CR, PR and antileukemic effect (ALE))</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>until 4 weeks after study drug intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and toxicity</measure>
    <time_frame>until 4 weeks after study drug intake</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+VPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks</description>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_label>Decitabine+VPA</arm_group_label>
    <arm_group_label>Decitabine+ATRA</arm_group_label>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VPA</intervention_name>
    <description>VPA starting on day 6 of first cycle continuously throughout all treatment cycles</description>
    <arm_group_label>Decitabine+VPA</arm_group_label>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <other_name>Valproic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRA</intervention_name>
    <description>ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle</description>
    <arm_group_label>Decitabine+ATRA</arm_group_label>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <other_name>All-trans retinoic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained according to international guidelines and local law;

          2. Male or female patients aged &gt; 60 years without upper age limit;

          3. Patients with primary or secondary AML according to WHO (≥ 20% blasts in the
             peripheral blood (pB) or bone marrow (BM)) who are not expected to benefit from
             standard remission-induction chemotherapy;

          4. Patients with &lt; 30 000 leukocytes/μl;

          5. Performance status ECOG 0, 1, 2;

          6. Creatinine &lt; 2.0 mg/dl (unless leukemia-related);

          7. Ability to understand the nature of the study and the study related procedures and to
             comply with them.

        Exclusion Criteria:

          1. AML of FAB subtype M3;

          2. Previous remission-induction chemotherapy for MDS or AML, previous allografting;

          3. Previous treatment with DAC, 5-azacytidine, VPA or another HDAC inhibitor, or ATRA;

          4. &quot;Low-dose&quot; chemotherapy (e.g. hydroxyurea, cytosine arabinoside (Ara-C), melphalan,
             clofarabine etc.) within 4 weeks prior to DAC treatment, except for cytoreduction of
             leukocytosis ≥ 30 000/μl with hydroxyurea or Ara-C as proscribed by the study protocol
             (section 7.3 and 7.4); the patient must have recovered from all clinically relevant
             reversible non-hematologic toxicities;

          5. Treatment with tyrosine kinase inhibitors, immunomodulating agents (IMIDS) or other
             investigational AML treatment within the last 4 weeks or in a time period of drug
             half-life x 5 (whatever is shorter) before the first administration of DAC;

          6. Treatment with cytokines within previous 4 weeks;

          7. Concomitant therapy which is considered relevant for the evaluation of efficacy or
             safety of the trial drug (i.e. other chemo- or immunotherapy);

          8. Other malignancy requiring treatment (previous chemotherapy for other malignancies is
             not an exclusion criteria);

          9. Cardiac insufficiency NYHA IV;

         10. Insufficient hepatic function (bilirubin, AST or ALT &gt; = 2.5 x Upper Limit of Normal
             (ULN)) (unless leukemia-related);

         11. Fatal hepatic function disorder during treatment with valproic acid in siblings;

         12. Hepatic porphyria;

         13. Manifest serious pancreatic function disorder;

         14. Plasmatic coagulation disorder not related to AML;

         15. Known active hepatitis B or C;

         16. Known HIV infection;

         17. Other uncontrolled active infections;

         18. Known allergy against soy beans or peanuts;

         19. Psychiatric disorder that interferes with treatment;

         20. Patient without legal capacity who is unable to understand the nature, significance
             and consequences of the study;

         21. Known hypersensitivity to, or intolerance of, one of the trial drugs, another retinoid
             or the excipients of the trial drugs;

         22. Concomitant use of any other investigational drug or participation in a clinical trial
             within the last thirty days before the start of this study; simultaneous participation
             in registry and diagnostic trials is allowed;

         23. Female patients who are pregnant or breast feeding;

         24. Fertile patients refusing to use safe contraceptive methods during the study (for
             details see clinical trial protocol section 5.3);

         25. Known or persistent abuse of medication, drugs or alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lübbert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology/Oncology, University of Freiburg Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Technischen Universität Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie-Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen GmbH</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Hagen</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm gGmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Lahr-Ettenheim</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU München</name>
      <address>
        <city>München</city>
        <zip>86175</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Münster Medical Center</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universität Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Villingen-Schwenningen</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1432-5</url>
    <description>Study protocol publication</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Michael Luebbert</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Low-dose Decitabine</keyword>
  <keyword>Valproic acid</keyword>
  <keyword>All-trans retinoic acid</keyword>
  <keyword>Older Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

